Dr. Reddy’s Laboratories is a global leader in generic pharmaceuticals, committed to expanding patient access to high-quality medicines at a fraction of brand costs. With a portfolio spanning over 230 products in North America alone, the company addresses a wide range of therapeutic categories and dosage forms, from oral solids and injectables to complex generics, peptides, and drug-device combinations. These products allow pharmacies to provide affordable treatment options while supporting healthcare system sustainability.
A distinguishing feature of Dr. Reddy’s generics business is its focus on first-to-market launches and complex formulations. For example, the launch of Lenalidomide Capsules, the generic equivalent of REVLIMID®, granted Dr. Reddy’s valuable 180-day exclusivity, reinforcing its ability to deliver specialty generics that significantly impact patient affordability. Beyond oncology, the company has expanded into areas such as long-acting injectables, peptides, and women’s health supplements, supported by patient services like co-pay assistance and specialty pharmacy partnerships.
Key Highlights of Dr. Reddy’s Generics Portfolio:
- 230+ products across retail, institutional, and OTC segments in North America.
- Complex generics: long-acting injectables, peptides, and drug-device combos.
- First-to-market exclusivities, including oncology therapies.
- Patient support services: hubs, reimbursement assistance, and clinical support for select therapies.
- Digital marketplace: DrReddysDirect.com streamlines procurement.
Globally, Dr. Reddy’s also operates in more than 14 European countries, offering generics, biosimilars, and OTC products. Subsidiaries like betapharm and Nimbus Health GmbH further extend its portfolio into consumer healthcare and medical cannabis.
